InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Life Sciences IP Focus 2012

  • Editorial

  • Interview: Robert Armitage, Eli Lilly

    The American Invents Act could have a big effect on the life sciences industry. Kevin Matha spoke with Robert A Armitage, senior vice president and general counsel at Eli Lilly, about the new legislative package

  • Interview: Looking back on decades of industry change

    Tom Ciotti and Kate Murashige of Morrison & Foerster have been involved with the life sciences industry for almost 50 years. Phillip Bausk spoke with them about the changes they have seen in that time

  • Europe: Patenting plant breeding

    Edward J Farrington of Inspicos considers the role of human intervention when acertaining the limits of patentability in plant breeding

  • Europe: Selection inventions

    Louise Tottie and Anette Romare of Valea outline important aspects of selection inventions relating to lists and ranges, to consider when drafting patent applications

  • Mexico: New practice on medical-use claims

    Agustín Azcatl, Daniel Sánchez and Pedro Herrera of Olivares & Cia explain the impact of rule changes on first medical-use claims

  • US: The America Invents Act

    Ha Kung Wong and John Kirkland of Fitzpatrick Cella Harper & Scinto use three scenarios to examine the impact of the Act and the future of paragraph IV litigation


profile

Managing IP

ManagingIP

ManagingIP profile

ICYMI: Our report on this week's #SCOTUS ruling in Star Athletica v Varsity Brands https://t.co/Rf3TWplNUrhttps://t.co/TrZ5YcvKQr

Mar 24 2017 01:35 ·  reply ·  retweet ·  favourite
ManagingIP profile

@Oblon_IP @PatentPostGrant Congratulations Scott! #mipawards

Mar 24 2017 01:13 ·  reply ·  retweet ·  favourite
ManagingIP profile

@KellyIPllp Well done to all at the firm!

Mar 24 2017 02:16 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


March 2017

Roundtable: The second medical use challenge – full transcript

Three leading patent specialists discussed one of the most challenging issues in IP at the moment – incentivising new uses for known drugs – at a recent roundtable discussion. The participants were: Jurgen Dressel, head of global patent litigation strategy, Novartis Pharma; Galit Gonen, VP and general counsel for Europe at Teva; and Professor Sir Robin Jacob, former Court of Appeal judge and professor at the Institute of Brand and Innovation Law, University College London



Most read articles

Supplements